Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Neoplasm
84%
Epidermal Growth Factor Receptor
72%
Liver Cell Carcinoma
63%
Non Small Cell Lung Cancer
61%
Overall Survival
61%
Chemotherapy
54%
Lung Cancer
50%
Cisplatin
41%
Progression Free Survival
39%
Diseases
32%
Lung Adenocarcinoma
27%
Adverse Event
25%
Gemcitabine
24%
Cytotoxicity
24%
Drug Resistance
23%
Placebo
23%
Colorectal Carcinoma
23%
Paclitaxel
22%
Tubulin
22%
Ramucirumab
21%
Protein Tyrosine Kinase Inhibitor
21%
IC50
21%
Combination Therapy
20%
microRNA
19%
Nanoparticle
18%
Oxaliplatin
18%
Osimertinib
18%
Pembrolizumab
18%
Mouth Squamous Cell Carcinoma
17%
Folinic Acid
17%
Epidermal Growth Factor Receptor Kinase Inhibitor
16%
Solid Malignant Neoplasm
16%
Sorafenib
15%
Fluorouracil
15%
Nasopharynx Carcinoma
15%
Head and Neck Squamous Cell Carcinoma
15%
Pancreas Cancer
14%
Alpha Fetoprotein
14%
Carcinogenesis
14%
Tumor Growth
13%
Erlotinib
13%
Breast Cancer
13%
Proteinase
12%
Cetuximab
12%
Irinotecan
12%
Afatinib
12%
Pharmacokinetic
12%
Biological Marker
12%
Head and Neck Cancer
12%
Colchicine
12%
Anticarcinogen
12%
Chemoradiation Therapy
12%
Gefitinib
12%
Photodynamic Therapy
12%
Squamous Cell Carcinoma
12%
Antiproliferative Activity
11%
Oligonucleotide
11%
Cathepsin S
10%
Pancreas Adenocarcinoma
10%
Cancer Chemotherapy
10%
Phosphotransferase
10%
Recurrent Disease
10%
Survival Rate
10%
Clinical Trial
9%
Monotherapy
9%
Programmed Death 1 Ligand 1
9%
Reactive Oxygen Metabolite
9%
Anticancer Drug
9%
STAT3 Protein
9%
Photosensitizer
9%
Bevacizumab
9%
Tolerability
9%
Antitumor Activity
9%
Arginine
8%
Abdominal Cancer
8%
Immunotherapy
8%
Nivolumab
8%
Binding Site
8%
Mouth Cancer
8%
Iron
8%
Docetaxel
8%
Microtubule Inhibitors
8%
Brain Metastasis
8%
Hepatitis B Virus
8%
Interleukin 6
7%
DNA Topoisomerase (ATP Hydrolysing)
7%
Immunoreactive Insulin
7%
Maximum Tolerated Dose
7%
Indole
7%
Atezolizumab
7%
Small Interfering RNA
7%
Metastatic Colorectal Cancer
7%
Circulating Tumor DNA
7%
Polyethylene Glycol
7%
Tumor Necrosis Factor
6%
Liver Cancer
6%
Phase II Trials
6%
Diarrhea
6%
Inflammation
6%
Medicine and Dentistry
Neoplasm
61%
Overall Survival
43%
Hepatocellular Carcinoma
39%
Non Small Cell Lung Cancer
35%
Epidermal Growth Factor Receptor
32%
Lung Cancer
28%
Progression Free Survival
21%
Malignant Neoplasm
20%
Cancer Cell
17%
Diseases
16%
Metastatic Carcinoma
16%
Ramucirumab
14%
Radiation Therapy
13%
Colorectal Carcinoma
13%
Cancer
13%
Pembrolizumab
12%
Oral Cancer
12%
Head and Neck Cancer
12%
Breast Cancer
11%
Placebo
11%
Lung Adenocarcinoma
11%
Tyrosine-Kinase Inhibitor
11%
Pancreas Cancer
10%
Epidermal Growth Factor Receptor Kinase Inhibitor
10%
Adverse Event
10%
Sorafenib
10%
Nivolumab
10%
Cancer Therapy
9%
Hazard Ratio
9%
Nasopharynx Carcinoma
9%
Arm
9%
Programmed Death-Ligand 1
9%
Prognostic Factor
9%
Autophagy
9%
Biological Marker
8%
Gemcitabine
8%
Recurrent Disease
8%
Pancreas Adenocarcinoma
8%
Programmed Death 1 Ligand 1
8%
microRNA
8%
Mouth Squamous Cell Carcinoma
8%
Chemoradiotherapy
8%
Non-Small Cell Lung Cancer
7%
Betel
7%
Proteinase
7%
Monotherapy
7%
Neck
7%
In Vitro
7%
Treatment Response
7%
Cetuximab
7%
Antineoplastic Activity
7%
Cathepsin B
7%
Oncology
6%
Carcinogenesis
6%
Head and Neck Squamous Cell Carcinoma
6%
Brain Metastasis
6%
Liquid Biopsy
6%
Cisplatin
6%
Cell Death
6%
Afatinib
6%
Liver Cancer
6%
Tumor Progression
6%
Clinical Trial
6%
Programmed Cell Death
6%
Osimertinib
6%
Carcinoma Cell
6%
Germ Cell
6%
Odds Ratio
6%
Next Generation Sequencing
6%
Cytotoxicity
6%
Cancer Growth
6%
Proportional Hazards Model
5%
Circulating Tumor DNA
5%
Quality of Life
5%
Contralateral
5%
Clinical Significance
5%
Cost-Effectiveness Analysis
5%
Tumor Imaging
5%
Cathepsin E
5%
Biliary Tract Cancer
5%
Elevated Alpha-Fetoprotein
5%
Family History
5%
Drug Resistance
5%
Nanoparticle
5%
DNA Mismatch Repair
5%
Cancer Registry
5%
Solid Malignant Neoplasm
5%
Erlotinib
5%
Cholangiocarcinoma
5%
Pemetrexed
5%
Oral Cavity
5%
Anticarcinogen
5%
Phosphotransferase
5%
Keyphrases
Ramucirumab
12%
IC50 Value
12%
Cancer Cells
11%
Overall Survival
11%
Advanced Hepatocellular Carcinoma
10%
Sorafenib
9%
Lung Cancer
9%
Taiwanese
9%
Taiwan
8%
Cancer Cell Lines
8%
Epidermal Growth Factor Receptor
7%
Head-and-neck Cancer
7%
Microtubules
7%
Tubulin
7%
EGFR mutation
6%
Cisplatin
6%
Colchicine Binding Site
6%
Antitubulin Agents
6%
Novel Class
6%
Phase II Study
6%
Erlotinib
5%
Gold Nanoparticles
5%
First-line Therapy
5%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
5%
Chemotherapy
5%
Liposomal Irinotecan
5%
Alpha-fetoprotein
5%
Tubulin Polymerization Inhibitors
5%
Antimitotic
5%
Benzenesulfonamide
5%
RAB37
5%
Metastatic Pancreatic Ductal Adenocarcinoma
5%
Autophagy
5%
Cell Cycle Arrest
5%
Hazard Ratio
5%
Cell Death
5%
Cancer Patients
5%
Non-small Cell Lung Cancer (NSCLC)
5%